Shares of Aileron Therapeutics Inc (NASDAQ:ALRN) have earned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Brokers have set a 12-month consensus price objective of $19.33 for the company and are expecting that the company will post ($0.46) EPS for the current quarter, according to Zacks. Zacks has also given Aileron Therapeutics an industry rank of 187 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research raised shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th.
In other news, major shareholder Apple Tree Partners Ii Lp sold 150,000 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $9.80, for a total transaction of $1,470,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 68.10% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of the company. California State Teachers Retirement System purchased a new stake in shares of Aileron Therapeutics during the 3rd quarter worth about $110,000. Vanguard Group Inc. purchased a new stake in shares of Aileron Therapeutics during the 2nd quarter worth about $111,000. Bank of New York Mellon Corp purchased a new stake in shares of Aileron Therapeutics during the 3rd quarter worth about $135,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Aileron Therapeutics during the 3rd quarter worth about $165,000. Finally, Endurant Capital Management LP grew its holdings in shares of Aileron Therapeutics by 24.0% during the 4th quarter. Endurant Capital Management LP now owns 85,997 shares of the company’s stock worth $906,000 after purchasing an additional 16,647 shares during the period. Institutional investors and hedge funds own 7.24% of the company’s stock.
Aileron Therapeutics (ALRN) traded up $0.19 during midday trading on Monday, hitting $7.88. 7,700 shares of the stock were exchanged, compared to its average volume of 22,774. Aileron Therapeutics has a one year low of $7.38 and a one year high of $15.48.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/22/1187314.html.
About Aileron Therapeutics
Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.
Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.